3 results
Approved WMOWill not start
Primary ObjectiveSafety Lead-in* Evaluate the safety of a high-dose regimen of encorafenib + binimetinib combination therapy in patients with BRAFV600-mutant melanoma who have asymptomatic brain metastasisPhase 2If the high-dose regimen is…
Approved WMORecruiting
The primary objective of this study is to investigate the stability of the fixation in the bone of the Legion HK Hinge Knee System in revision TKA. The secondary objective of this study is to assess the functional performance/ effectiveness (…
Approved WMOCompleted
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.